Opinion: Writer sees biotechs entering 2005 with "good momentum"

12/30/2004 | TheStreet.com

Although 2004 is replete with "blowups" of biotechnology companies, the sector is entering 2005 with good momentum, the most heavily capitalized staying stronger than small-cap firms, according to a senior writer at TheStreet.com. U.S. cutbacks in Medicare reimbursements next year could lead to a trend change in drug usage and affect biotech companies such as Amgen, Genentech and Biogen Idec.

View Full Article in:

TheStreet.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Compliance Specialist
MJHS
Brooklyn, NY
Director of Utilization Management
Meridian Health Plan
Chicago, IL
Senior Manager, Healthcare Reform
Avalere Health
Washington, DC
Regulatory Senior Managing/Principal Engineer/Scientist
Exponent
Menlo Park, CA
Director of Claims
Meridian Health Plan
Detroit, MI